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ScienceDirectRespiratory syncytial virus causes significant morbidity and
mortality in both developed and developing countries, and a
vaccine that adequately protects from severe disease remains
an important unmet need. RSV disease has an inordinate
impact on the very young, and the physical and immunological
immaturity of early life complicates vaccine design. Defining
and targeting the functional capacities of early life immune
responses and controlling responses during primary antigen
exposure with selected vaccine delivery approaches will be
important for protecting infants by active immunization.
Alternatively, vaccination of older children and pregnant
mothers may ameliorate disease burden indirectly until infants
reach about six months of age, when they can generate more
effective anti-RSV immune responses.
Address
Vaccine Research Center, National Institute of Allergy and Infectious
Disease, National Institutes of Health, Bethesda, MD, USA
Corresponding author: Ruckwardt, Tracy J (truckwardt@mail.nih.gov)
Current Opinion in Virology 2016, 16:151–157
This review comes from a themed issue on Viral immunology
Edited by Liisa K Selin and Allan J Zajac
For a complete overview see the Issue and the Editorial
Available online 15th March 2016
http://dx.doi.org/10.1016/j.coviro.2016.01.003
1879-6257/Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/li-
censes/by-nc-nd/4.0/)
Introduction
Respiratory syncytial virus (RSV) is a globally ubiquitous
pathogen that commonly results in upper respiratory
infection. It has a highly infectious nature, resulting in
infection of up to 70% of children in their first year of life,
and almost all children by two years of age [1]. A large
proportion of primary infection events result in lower
respiratory tract infection (LRTI), resulting in hospitali-
zation for approximately 2–3% of infected infants. LRTI
can be manifested as bronchiolitis, pneumonia, and
wheezing and can ultimately result in respiratory failure
and death. Most disease and death due to RSV-associated
LRTI occur in resource-poor, developing countries.
Globally, RSV is estimated to cause about 33.8 million
new cases of LRTI in children under five [2]. Recent
meta-analysis of global causes of death in children in the
first year of life highlights the considerable role of LRTIwww.sciencedirect.com and places RSV as the second most-likely single pathogen
to cause death in children less than 1 year of age [3].
These recent epidemiological analyses illustrate the
health and economic toll of RSV, and implicate it as
one of the most important pathogens of early childhood.
Prematurity, immunosuppression, and genetic or congeni-
tal factors are among many risk factors known to predispose
infants to RSV-associated LRTI, but the majority of chil-
dren who develop a LRTI requiring hospitalization do not
have an identifiable risk factor other than young age [4].
Several key aspects of early life underlie the susceptibility
of young infants to LRTI following RSV infection. Physi-
cal and immunological immaturity causes infants younger
than three months to be the most prone to severe disease.
Airway size, in particular, is a problem in neonates and
young infants because obstruction from sloughed epitheli-
um, mucus, fibrin, and inflammatory debris is a major factor
in disease pathogenesis. The months following birth are
a period of dramatic development of the lung architecture
and cellular functions [5,6], including the awakening and
education of immunological effector mechanisms that
must learn to deal with a world laden with both commensal
and pathogenic microorganisms [7].
Recent scientific advances have made the prospects of
significantly diminishing the morbidity and mortality
caused by RSV through vaccination a foreseeable possi-
bility, and may lead to a change in the current landscape
of RSV [8]. This is particularly significant for the neona-
te’s evolving immunological repertoire because for many
infants, RSV may be the first pathogen encountered in
life. Therefore, RSV is one of the first tests of immune
defenses and a significant priming event for future adap-
tive responses. Here, we discuss some recent findings on
the limitations of early life immune responses to natural
infection and vaccination, the likely requirements to
counter these limitations, and the prospects for protecting
infants from severe disease by either direct or indirect
mechanisms.
Infant innate responses to natural RSV
infection
Infants with no prior exposure to RSV must initially rely
solely on innate defenses. These early defenses must
combat the suppressive mechanisms of early life. The
neonatal immune environment can be considered toler-
ance-inducing as a mechanism to protect from the loss of
maternal or self-tolerance and potential for immunopath-
ological responses to developing organs. It has long beenCurrent Opinion in Virology 2016, 16:151–157
152 Viral immunologyrecognized that infants suffer disproportionately from
infectious disease due to this suppressive environment
and the qualitative and quantitative deficiencies of newly
generated immune cells. More recently, these deficien-
cies are recognized as deficiencies by design, as studies in
the ontogeny of early life immunity paint a picture of
specialized early life immune function [7,9–12]. Early
life immunity has been found to display aspects of layer-
ing, where cells derived from fetal hematopoietic stem-
progenitor cells (HSPC) develop in utero and can exert
age-specific, innate-like, or regulatory functions and cells
derived from ‘adult’ HSPC following parturition possess
distinct functional profiles. A comparative microarray
analysis of human fetal and adult naı¨ve CD4+ T cells
demonstrated that while phenotypically similar, these
subsets are functionally distinct. Fetal CD4+ T cells
are biased toward immune tolerance and are more likely
to differentiate into regulatory T cells (Tregs) after
stimulation [13]. In this way, early life immunity may
be considered distinct and specialized in the needs of
early life rather than deficient.
Immunomodulation in early life is due to both soluble
and cellular mechanisms [7,14]. Immunosuppressive
plasma factors such as adenosine and anti-inflammatory
cytokines dampen inflammatory responses, and trans-
forming growth factor beta (TGFb) has been found to
mediate suppression of natural killer (NK) cell function.
Tregs, one potential source of TGFb, have been found in
higher numbers in newborns and preterm infants and
possess immunosuppressive functions during early life
[15,16]. Another cellular source of immunosuppression,
CD71+ erythroid cells, are prevalent during early life and
may compromise host defenses [17]. Neonatal neutro-
phils produce potentially anti-inflammatory and Th2-
promoting IL-6, yet have dampened phagocytic and
killing mechanisms [7]. Further work is necessary to
understand the integrated contribution of these many
immunomodulatory mechanisms on the inability of
infants to effectively combat respiratory infections, par-
ticularly RSV.
Dendritic cells (DCs), are critical orchestrators of both
innate and adaptive immunity. DCs are specialized in
recognizing and integrating signals conferred by pattern
recognition receptors (PRRs), and RSV is recognized by
toll-like receptor (TLR)4, TLR3, TLR2/6, TLR7/8 and
retinoic acid-inducible gene I (RIG-I) [4]. Neonates
have responses distinct from those of adults following
stimulation by most TLR agonists, and TLR agonists as
well as other adjuvants have been found to have age-
dependent immune activity [18]. Studies of dendritic
cells in the lungs of human infants are hampered by both
ethical and technical hurdles. While there are several
animal models used to study RSV [19–22], none
completely recapitulate disease pathogenesis in infants.
Additionally, most studies focus on infection of adultCurrent Opinion in Virology 2016, 16:151–157 animals, which does not address the unique context of
the infant respiratory tract and immune system. Neonatal
mice have been used to help define basic immunological
mechanisms underlying early life immune responses to
RSV [23]. Limitations in plasmacytoid dendritic cell
(PDC) function and type I interferon production in neo-
natal mice was shown to be one mechanism promoting
Th2-biased immunopathology following RSV infection
[24]. Studies in human neonates and very young children
also demonstrated that early-life PDCs have limited type I
interferon following exposure to RSV [25]. A thorough
understanding of the limitations of dendritic cells in the
lung must include local lung-migratory DC populations,
namely CD103+ and CD11b+ DC subsets, known to
induce adaptive T cell responses. We have described a
dramatic early-life transition in the response of these two
populations of dendritic cells following RSV infection in
neonatal mice. In addition to the rapidly changing compo-
sition of these important dendritic cells subsets in the lung
and mediastinal lymph node, both CD103+ and CD11b+
dendritic cells of neonatal mice are less efficient at antigen
uptake and processing, and have lower costimulatory mol-
ecule expression than their adult counterparts [26].
These, and other limitations of early life DCs can affect
their ability to induce adaptive immune responses.
For a more comprehensive examination of the ontogeny
of early life innate immune responses and innate
responses to RSV infection in infants, please see several
recently published in depth reviews covering these topics
[4,7,9,27,28].
Infant adaptive responses to natural RSV
infection
The generation of effective anti-viral adaptive immunity
relies on instruction by the innate immune response
(elegantly reviewed in [29]). Antigen presenting cells
(APCs), in particular, exert exquisite control, dictating
both the induction and the downstream function of
adaptive effector cells. Early life deficiencies in innate
immunity, particularly in APCs, translate into altered or
inferior T and B cell immunity. As one example of this,
we have shown that the previously-described early life
changes in the dynamics and function of lung-migratory
DCs is directly linked to the distinct CD8+ T cell
response established in neonatal mice. In particular,
the decreased ability of neonatal DCs to provide co-
stimulatory support alters the immunodominance hierar-
chy of responding T cells [26,30]. Every difference in
early life DC function, such as how they take up and
process antigens or produce cytokines, may affect adap-
tive immunity.
While CD8+ T cells have been shown to contribute to
disease in mouse models, they have not been shown to be
detrimental in RSV-infected infants. In fact, they have
been found to coincide with convalescence in infants withwww.sciencedirect.com
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been noted in a study involving autopsies of infants that
died of severe disease [32]. CD4+ T cell responses in
young infants undergoing disease have demonstrated a
Th1 to Th2 imbalance, and Th2-driven pathology was
associated with enhanced disease following formalin-
inactivated RSV (FI-RSV) immunization and may be a
factor in airway reactivity and wheezing common in
infants with severe RSV disease [4,8]. Th17 responses
to RSV have also been documented [33], another poten-
tial result of the inability of dendritic cells to strongly
polarize toward Th1 following RSV infection [4].
Neutralizing antibodies can effectively protect from se-
vere RSV disease as demonstrated by the efficacy of
Synagis, a monoclonal antibody (mAb) administered to
premature and other high-risk infants. However, infants
are known to have significantly diminished antibody
responses compared to adults and several intrinsic and
extrinsic B cell limitations have been described
[7,34,35]. For the first several months of life, B cells
have a limited ability to promote somatic mutation re-
quired for affinity maturation. A recent study on the
development of RSV-specific antibody following natural
infection in infancy demonstrated that RSV-neutralizing
antibody was unlikely to develop in infants under four
months of age. Infants began to show significant increases
in neutralizing capacity after the age of four months, with
a dramatic increase in infants infected after six months of
age. These data suggest that vaccines that mimic natural
infection may be ineffective if administered prior to
four months of age [36]. A more detailed summary of
T and B cell responses to natural RSV infection, and their
contribution to disease, is provided in recent reviews
[4,27,37].
Recent studies in nonhuman primates have demonstrated
how regulatory and suppressive mechanisms can impact
both the generation and function of adaptive immunity in
the lung. Holbrook et al. studied antibody responses in
infant African green monkeys (AGM) infected with in-
fluenza [38]. They found similar systemic influenza-spe-
cific IgG responses in infants and adults, yet infants had
lower influenza-specific IgG and demonstrated less neu-
tralizing activity in upper respiratory tract secretions. This
was associated with higher viral titers and increased
pulmonary damage in infants. Interestingly, while adult
AGM showed robust generation of bronchus associated
lymphoid tissue (BALT) following infection, infants
demonstrated a near absence of these tertiary lymphoid
tissues. This may be due to increased levels of Tregs,
which may inhibit BALT formation, in the lungs of AGM
infants [38]. Further studies on the dynamics of immune
responses in the lung specifically will help elucidate
potential mechanisms of suppression, and may suggest
approaches for generating local immune responses to
effectively counter respiratory pathogens.www.sciencedirect.com Prospects for direct protection of the
vulnerable infant population
A failed vaccine trial nearly 50 years ago has given the
vaccination of infants against RSV an unfortunate legacy,
and many are wary of the potential to enhance disease in
infant populations using protein-based or inactivated
virus vaccines [39,40]. FI-RSV vaccine administered in
the 1960s was an adaptation of an approach successfully
used for preventing disease from pathogens such as polio,
but in the case of RSV resulted in enhanced disease after
natural infection and the deaths of two children [41]. FI-
RSV elicited an abundance of undesired responses not
predicted by previous experiences with formalin-inacti-
vated vaccines. Antibody with low neutralizing activity
was induced and associated with immune complex depo-
sition. Another prominent feature of FI-RSV immuniza-
tion was the presence of eosinophilia [41,42] and animal
studies indicate that priming with FI-RSV induces CD4+
T cells biased toward Th2 with low induction of CD8+ T
cells [8].
Since the 1960s, relatively few attempts have been made to
vaccinate infants under six months of age against RSV.
Trials of live-attenuated virus vaccine candidates, known
not to be associated with the FI-RSV vaccine-enhanced
disease, have caused congestion and other side-effects that
have so far been unacceptable for use in infants and it has
proven difficult to strike the balance between attenuation
and immunogenicity [39]. Several newer candidates for
active vaccination of infants are in the pipeline, and will be
thoroughly evaluated for safety, generation of protective
responses, and establishment of durable immunity in
infants if regulatory challenges can be overcome. These
vaccines must also generate protective responses despite
potential interference from maternal antibodies [43].
As the current infant immunization schedule suggests,
immune responses to effectively counter disease can be
elicited in the young by repeated immunizations. Nearly
all infant vaccines, including the hepatitis B vaccine first
administered at birth, rely on repeated exposure to gen-
erate sufficiently protective memory responses. BCG, a
potent immune stimulator given to infants outside of the
US, can stimulate immune responses in infants similar to
those of adults after a single dose [34]. The ability of
infants to respond to vaccination appears to depend on
nature and strength of the stimulus, with the responses to
different vaccines or vaccine components in infants
approaching those of adults at different ages [18,34].
Immunosuppressive features of infant immunity, as well
as the inherent ability of the lung itself to negatively
regulate effector cell function [34], make the choice of
antigen and the context in which it is administered critical
choices in the design of infant vaccines against RSV.
A better understanding of RSV structure has improved
our ability to tailor vaccine antigens to elicit protectiveCurrent Opinion in Virology 2016, 16:151–157
154 Viral immunologyresponses in young infants. Recent studies have solved
the structure of the pre-fusion conformation of the RSV F
trimer (pre-F) [44]. Antibodies have led to the definition
of at least three sites unique to pre-F surfaces; D25, AM22
and 5C4 mAbs to site Ø [44,45], MPE8 mAb to a site
common to RSV and human metapneumovirus [46], and
AM14 to a quaternary epitope on the pre-F trimer [47].
Antibodies to pre-F-specific surfaces have much higher
neutralization potency than antibodies to the surfaces
shared between the pre-fusion and post-fusion (post-F)
forms like palivizumab (site II) or 101F (site IV). More
than 90% of neutralizing activity in samples from indi-
viduals ranging from 7 to 93 years of age can be adsorbed
by pre-F, whereas only about 20% is adsorbed by post-F
[48]. Delivery of pre-F as a subunit protein, virus-like
particle (VLP), chimeric virus, or other gene-based
approaches may facilitate the induction of these potently
neutralizing antibodies in young infants [49].
Equally as important as antigen choice, the use of adju-
vants in infants should be based on age-specific informa-
tion about PRR responsiveness [18]. For induction ofFigure 1
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the inclusion of TLR agonists is one attractive approach
[34]. Targeting DCs, particularly DC populations located
in the lung, is critical to promoting the generation of more
mature adaptive responses (Figure 1). We have found that
TLR3, TLR4 and TLR9 agonists administered at the
time of RSV infection promote the generation of adult-
like epitope hierarchy in neonatally infected mice, as well
as promote the maturation of lung-migratory CD103+ and
CD11b+ DC subsets (Malloy, A et al., abstract 1354,
IDWeek, Philadelphia, PA, October 2014). The recently
demonstrated efficacy of the RTS,S/ASO1 malaria vaccine
in young infants, which was adjuvanted with the TLR4
agonist monophosphoryl lipid A and the saponin QS21
formulated in liposomes, shows promise for combining
TLR agonists with non-TLR adjuvants [50]. Engagement
of multiple TLRs has been shown to have synergistic
effects on neonatal dendritic cells, and may be the key to
the efficacy of BCG in neonates, which simultaneously
stimulates five TLRs [34]. Little is known about the
function of follicular dendritic cells (FDC) in early-life.
FDC express an array of TLRs [51], and TLR ligationCurrent Opinion in Virology
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nize and maintain germinal centers, and support the
development of high-affinity antibodies. Despite techni-
cal hurdles, this is an important area for future investiga-
tion. For an infant vaccine, special consideration of the
potential of TLR agonists to stimulate Tregs should be
given, as different TLR agonists have been shown to
preferentially expand effector T cells over Tregs, and
vice versa [16].
Prospects for indirect protection of the infant
population
While infants are the highest priority target for prevention
of severe outcomes of RSV infection, difficulties in elicit-
ing protection in this group through active immunization
have led to strategies to diminish the impact of RSV on
this age group indirectly by boosting adaptive immune
responses of pregnant women or older children.
Promoting protection via enhancing passive transfer of
maternal antibody is not a strategy unique to RSV.
Immunization of pregnant mothers has proven an effec-
tive approach against tetanus, pertussis and influenza
[52]. Maternally-transferred RSV antibody has been
found to be associated with a lower risk of infection in
infants when antibody titers are maintained above levels
that are considered protective [53]. It is estimated that
transfer of high concentrations of RSV-specific antibody
from vaccinated mothers could extend protection up to
six months of age. This approach could be coupled with
active vaccination in infants over 6 months of age, at
which point immune responses to vaccination are more
likely to elicit neutralizing antibody and prevent disease
following natural infection.
In addition to vaccinating mothers, school-aged children
are a promising target population to limit transmission to
infants. In-depth household studies in rural Kenya have
estimated the average duration of viral shedding as
11.2 days, longer than previously estimated, and more
than 10% of infection episodes resulted in shedding for
21 days or more. Shedding was shown to be strongly
associated with age and the severity of infection [54].
Additional studies in these same cohorts revealed that
older, school-aged siblings are most often responsible for
transmitting RSV to within-household infants [55]. A
vaccine that would induce a level of protection equivalent
to natural infection (around 6 months) in school-aged
children is predicted to reduce RSV occurrence in those
less than one year old by 35% within 10 years. This is
comparable to the estimated 41% protection that might
be achieved by directly vaccinating 3-month old babies
[56]. In addition to the beneficial impact on infant infec-
tion, targeting reduction of shedding in school-aged chil-
dren may help mitigate disease in the elderly and other
high-risk groups.www.sciencedirect.com Conclusions
RSV remains a serious pathogen for which there is no
vaccine. While the virus is contained in the upper airways
in the majority of RSV-infected infants, millions of chil-
dren are hospitalized annually as a result of LRTI.
Limitations in both innate and adaptive immunity in
early life contribute to disease, and infection at a young
age may prime infants for suboptimal and rapidly waning
immune responses to subsequent exposures of RSV. This
may be one reason why natural infection can provide
protection against LRTI, but not prevent upper respira-
tory tract infections that recur throughout life.
Immunization of pregnant women and school-aged chil-
dren is expected to significantly diminish the morbidity
and mortality of RSV in the very young. In order to
achieve efficacy following direct active immunization
of infants, fundamental changes will need to be made
to the way that the immune system experiences RSV
antigens. An increased understanding of infant immunity
will be necessary, particularly in the respiratory tract.
While generating protective responses against RSV
appears to be very easy in adult, immunocompetent
animals, few studies involve testing vaccine candidates
or evaluating the response to infection in neonatal ani-
mals. A better understanding of responses in the lung, and
the lung draining lymph nodes will help inform vaccine
design for infants.
Age-specific vaccine strategies will need to counter the
suppressive nature as well as harness the strengths of
neonatal immunity. This may be accomplished by careful
selection of TLR agonists most likely to promote adult-
like responses and select for effector rather than regula-
tory responses. Increasing the potential of APCs to induce
mature adaptive responses will be a critical function of an
infant RSV vaccine. Coupled with immunogen design
targeted at promoting the most potent antiviral responses,
direct protection of infants from RSV may be possible in
the future.
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